Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Q32 Bio (QTTB)
NASDAQ:QTTB
Holding QTTB?
Track your performance easily
QTTB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.24 - $43.50
Previous Close$43.48
Volume236.63K
Average Volume (3M)99.72K
Market Cap
$524.36M
Enterprise Value$435.21M
Total Cash (Recent Filing)$107.65M
Total Debt (Recent Filing)$18.50M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.00
Shares Outstanding12,059,786
10 Day Avg. Volume137,961
30 Day Avg. Volume99,718
Standard Deviation0.26
R-Squared0.00476
Alpha-0.00170
Financial Highlights & Ratios
Price to Book (P/B)15.65
Price to Sales (P/S)282.07
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit376.48
Enterprise Value/Ebitda-6.77
Forecast
1Y Price Target
$71.33Price Target Upside64.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Q32 Bio News
PremiumCompany Announcements
Q32 Bio Advances in Atopic Dermatitis Treatment Trial
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentBempikibart is advancing with positive momentum as it undergoes evaluation in Phase 2 trials, promising potential breakthroughs in biologic therapeutics.
Clinical Trial ResultsADX-097 has shown promising results in a Phase 1 study, indicating the medication's tolerability and effectiveness in achieving complete complement inhibition in target tissues.
Financial HealthThe combined company is bolstered by a robust cash balance, ensuring a solid financial runway and supporting its innovative research and development activities.
Bears Say
Clinical Trial ResultsResults from patients two and three in the clinical trial were underwhelming, with patient two's diet self-liberalization and patient three's immature data.
Corporate RestructuringHomology is cutting its workforce by 87% and halting development efforts on its pipeline assets as management explores strategic alternatives.
Strategic DirectionManagement has announced a pause on all ongoing programs and is seeking strategic alternatives for the business due to a challenging financing environment.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
QTTB FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest stock price was $8.24 and its highest was $43.50 in the past 12 months.
What is Q32 Bio’s market cap?
Currently, no data Available
When is Q32 Bio’s upcoming earnings report date?
Q32 Bio’s upcoming earnings report date is Nov 12, 2024 which is in 64 days.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Aug 08, 2024. The company reported -$1.42 earnings per share for the quarter, missing the consensus estimate of -$0.997 by -$0.423.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio does not currently pay dividends.
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 12,059,786 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of -$1.42 in its last earnings report, missing expectations of -$0.997. Following the earnings report the stock price went down -10.648%.
Which hedge fund is a major shareholder of Q32 Bio?
Among the largest hedge funds holding Q32 Bio’s share is Platinum Investment Management. It holds Q32 Bio’s shares valued at 2M.
---
Q32 Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.33 (64.05% Upside)
$71.33 (64.05% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 36.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 20.3%
Last 30 Days ▲ 20.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.98%
12-Months-Change
Fundamentals
Return on Equity
-85.06%
Trailing 12-Months
Asset Growth
-26.65%
Trailing 12-Months
Company Description
Q32 Bio
Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.
---
QTTB Stock 12 Month Forecast
Average Price Target
$71.33
▲(64.05% Upside)
Technical Analysis
Best Analysts Covering QTTB
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+43.73%
reiterated a buy rating last month
Copying Thomas Smith's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +43.73% per trade.
---